Professional Documents
Culture Documents
Gkab 953
Gkab 953
Gkab 953
Received September 09, 2021; Revised September 29, 2021; Editorial Decision September 30, 2021; Accepted October 04, 2021
* To
whom correspondence should be addressed. Tel: +86 189 8946 6518; Fax: +86 0571 8820 8444; Email: zhufeng@zju.edu.cn
Correspondence may also be addressed to Yunqing Qiu. Email: qiuyq@zju.edu.cn
Correspondence may also be addressed to Yuzong Chen. Email: chenyuzong@sz.tsinghua.edu.cn
†
The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.
C The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work
is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Nucleic Acids Research, 2022, Vol. 50, Database issue D1399
also the comparative data with respect to other bioac- and adopted ontology of this database were also provided
tive agents and other targets. Such comparative data in- in the TTD website.
clude the knowledge of poor binders or non-binders of
individual target that are useful for developing drug dis-
POOR BINDERS AND NON-BINDERS OF THERAPEU-
covery tool of enhanced performance (5–7); the informa-
TIC TARGETS
tion of prodrugs that facilitates drug design by improv-
ing pharmacokinetic/pharmacodynamic features (8); the Molecular docking is a widely-used structure-based drug
co-targets of therapeutic targets that facilitate the investi- discovery method (17), which employs scoring functions
gations of multi-target strategies (9), off-target (10,11) & for scoring the binding of molecules to a target site (25).
undesired effect (9); the collective structure-activity land- Poor binders and non-binders are useful decoy molecules
scapes of drugs against individual target that reveal impor- for the development of the scoring functions (6). AI meth-
tant pharmaceutical features such as activity cliffs (12); and ods have also been extensively explored to develop bioac-
the drugs’ profiles of their drug-like properties that provide tive molecule and pharmaceutical property screening tools,
Table 1. Accumulation of drugs and their corresponding targets in the latest and previous versions of TTD database
TTD statistics for targets and drugs
2022 2020 2018 2016 2014 2012 2010
All targets 3578 3419 3101 2589 2360 2025 1894
Successful targets 498 461 445 397 388 364 348
Clinical trial targets 1342 1191 1121 723 461 286 292
Preclinical/patented targets 185 155 0 0 0 0 0
Research targets 1553 1612 1535 1469 1467 1331 1254
All drugs 38 760 37 102 34 019 31 614 20 667 17 816 5028
Approved drugs 2797 2649 2544 2071 2003 1540 1514
Clinical trial drugs 10 831 9465 8103 7291 3147 1423 1212
Preclinical/patented drugs 5009 4845 0 0 0 0 0
Experimental drugs 20 123 20 143 18 923 17 803 14 856 14 853 2302
the structures of the prodrug and its parent drug were drawn other than their originally intended primary target (10). On
using ChemDraw based on the structures reported in each the one hand, such beneficial effects of off-target have been
corresponding literature. As shown in Figure 1, both the explored for drug repurposing against complex diseases
detailed data and structures of prodrugs were explicitly de- (36–39); on the other hand, off-target activity may in some
scribed in the TTD prodrug page. All in all, a total of 534 instances lead to undesirable effect (40). Based on multiple
prodrug-drug pairs of 91 STs and 30 CTs were collected to targets of drugs, one can define the co-targets of a thera-
this update of TTD. peutic target as the additional targets of all drugs target-
ing the therapeutic target. In other words, these co-targets
represent both the targets co-modulated by a multi-target
CO-TARGETS OF THERAPEUTIC TARGETS
drug (5) and the off-target of a drug (11). Thus, those co-
Many drugs are known to interact with more macromolec- targets of a therapeutic target were first collected by review-
ular targets than their intended primary therapeutic target. ing PubMed literatures (34) by combining the target name
In particular, a multi-target drug produces its therapeutic with the keywords ‘multi-target’, ‘off-target’, ‘multiple tar-
effect by modulating multiple targets (9). Some clinical trial gets’, ‘poly-pharmacology’, ‘co-targets’, ‘co-targeting’, etc.
drugs have been found to produce their therapeutic effects Second, all these literatures were manually checked to dis-
via interacting with off-targets, i.e., a macromolecular target cover those having the information of co-targets, and the
Nucleic Acids Research, 2022, Vol. 50, Database issue D1401
(12,45,46). Such structure-activity relationships can be fur- the bottom of Figure 3) drug-like properties, which was dis-
ther evaluated by the collective structure-activity landscape played using the hierarchical clustering map, heatmap and
of all known binders of studied target. As described in Fig- bar plot. The bar color indicates the highest clinical status
ure 2, all known binders of a target were clustered based of the corresponding drugs (approved, clinical trial, etc.).
on their structural similarities, each binder was represented Users can move the mouse over the bar to find the basic
by a colored bar with its height proportional to the level of information (status, PubChem CID, property, etc.) of spe-
target binding activity (–log IC50 , –log Ki, etc.) and color cific drugs, and the detailed information of each drug can
indicating each binder’s clinical status (orange, yellow, blue be also found by clicking that drug. Within each graph, the
and grey denote approved, clinical, discontinued and inves- known drugs of a target were clustered according to their
tigative drugs, respectively). The clustering of all binders similarities in drug-like properties, which was constructed
of target was constructed using the sequential steps as fol- by a process similar to that described in previous section.
lows. First, the molecular fingerprints of all binders were Each drug was represented by a vertical line with the am-
computed using R package ChemmineR (47). Second, the plitude proportional to the values of drug-like property. All
Figure 2. A typical plot in TTD showing the chemical structure-based activity landscape for a target. All known drugs of a target are clustered based on
their structural similarity. Moreover, the binding activity (e.g. –log IC50 , -logKi) for each drug against the target is represented by bar chart. The color of
the bar indicates the highest clinical status of the corresponding drug (approved, clinical trial, etc.). Users can move the mouse over the bar to get the basic
information (status, PubChem CID, activity, etc.) of each drug. The detailed drug data can be found by clicking that particular drug.
D1404 Nucleic Acids Research, 2022, Vol. 50, Database issue
Figure 3. A typical plot in TTD providing the information of the drug-like property-based profile for a target. All known drugs of a target are clustered
based on multiple (the top plot) or single (six plots at the bottom) drug-like properties, which is displayed using the hierarchical clustering map, heatmap
and bar plot. The bar color indicates the highest clinical status of the corresponding drugs (approved, clinical trial, etc.). The user can move the mouse
over the bar to find the basic data (status, PubChem CID, property, etc.) of that drug. The detailed drug data can be found by clicking that drug.
Nucleic Acids Research, 2022, Vol. 50, Database issue D1405
multi-entry target and drug similarity searching. Therefore, 2. Santos,R., Ursu,O., Gaulton,A., Bento,A.P., Donadi,R.S.,
a multi-entry target similarity searching and a multi-entry Bologa,C.G., Karlsson,A., Al-Lazikani,B., Hersey,A., Oprea,T.I.
et al. (2017) A comprehensive map of molecular drug targets. Nat.
drug similarity searching facility was introduced, where the Rev. Drug Discov., 16, 19–34.
users can upload a file of multiple protein sequences or 3. Licursi,V., Conte,F., Fiscon,G. and Paci,P. (2019) MIENTURNET:
multiple molecular structures for finding TTD targets or an interactive web tool for microRNA-target enrichment and
drugs that are similar in sequence or structure. Particularly, network-based analysis. BMC Bioinformatics, 20, 545.
the target similarity searching is based on the BLAST al- 4. Yin,J., Li,X., Li,F., Lu,Y., Zeng,S. and Zhu,F. (2021) Identification of
the key target profiles underlying the drugs of narrow therapeutic
gorithm. Input with one protein sequence or a batch up- index for treating cancer and cardiovascular disease. Comput. Struct.
load of multiple sequences for similarity search is now avail- Biotechnol. J., 19, 2318–2328.
able in the latest version of TTD. The identified targets are 5. Bajusz,D., Wade,W.S., Satala,G., Bojarski,A.J., Ilas,J., Ebner,J.,
ranked according to the BLAST outcomes. Moreover, the Grebien,F., Papp,H., Jakab,F., Douangamath,A. et al. (2021)
Exploring protein hotspots by optimized fragment pharmacophores.
drug similarity searching is based on Tanimoto coefficients. Nat. Commun., 12, 3201.
The compound structure is first converted to PubChem Fin- 6. Seeliger,D. and de Groot,B.L. (2010) Ligand docking and binding
DrugBank 5.0: a major update to the DrugBank database for 2018. precision, accuracy, and robustness of label-free proteome
Nucleic Acids Res., 46, D1074–D1082. quantification by optimizing data manipulation chains. Mol. Cell.
21. Wang,Y., Zhang,S., Li,F., Zhou,Y., Zhang,Y., Wang,Z., Zhang,R., Proteomics, 18, 1683–1699.
Zhu,J., Ren,Y., Tan,Y. et al. (2020) Therapeutic target database 2020: 40. Lounkine,E., Keiser,M.J., Whitebread,S., Mikhailov,D., Hamon,J.,
enriched resource for facilitating research and early development of Jenkins,J.L., Lavan,P., Weber,E., Doak,A.K., Cote,S. et al. (2012)
targeted therapeutics. Nucleic Acids Res., 48, D1031–D1041. Large-scale prediction and testing of drug activity on side-effect
22. Avram,S., Bologa,C.G., Holmes,J., Bocci,G., Wilson,T.B., targets. Nature, 486, 361–367.
Nguyen,D.T., Curpan,R., Halip,L., Bora,A., Yang,J.J. et al. (2021) 41. UniProt, C. (2021) UniProt: the universal protein knowledgebase in
DrugCentral 2021 supports drug discovery and repositioning. Nucleic 2021. Nucleic Acids Res., 49, D480–D489.
Acids Res., 49, D1160–D1169. 42. Wu,T., Nagle,A., Kuhen,K., Gagaring,K., Borboa,R., Francek,C.,
23. Armstrong,J.F., Faccenda,E., Harding,S.D., Pawson,A.J., Chen,Z., Plouffe,D., Goh,A., Lakshminarayana,S.B. et al. (2011)
Southan,C., Sharman,J.L., Campo,B., Cavanagh,D.R., Imidazolopiperazines: hit to lead optimization of new antimalarial
Alexander,S.P.H., Davenport,A.P. et al. (2020) The IUPHAR/BPS agents. J. Med. Chem., 54, 5116–5130.
Guide to Pharmacology in 2020: extending immunopharmacology 43. Teli,M.K., Kumar,S., Yadav,D.K. and Kim,M.H. (2021) In silico
content and introducing the IUPHAR/MMV guide to malaria identification of prolyl hydroxylase inhibitor by per-residue energy
pharmacology. Nucleic. Acids. Res., 48, D1006–D1021. decomposition-based pharmacophore approach. J. Cell. Biochem.,
structure-mutation-activity relationship tests (QSMART) model for 72. Paananen,J. and Fortino,V. (2020) An omics perspective on drug
protein kinase inhibitor response prediction. BMC Bioinformatics, target discovery platforms. Brief. Bioinform., 21, 1937–1953.
21, 520. 73. Fortino,V., Wisgrill,L., Werner,P., Suomela,S., Linder,N., Jalonen,E.,
61. Rella,M., Rushworth,C.A., Guy,J.L., Turner,A.J., Langer,T. and Suomalainen,A., Marwah,V., Kero,M., Pesonen,M. et al. (2020)
Jackson,R.M. (2006) Structure-based pharmacophore design and Machine-learning-driven biomarker discovery for the discrimination
virtual screening for novel angiotensin converting enzyme 2 between allergic and irritant contact dermatitis. Proc. Natl. Acad. Sci.
inhibitors. J. Chem. Inf. Model., 46, 708–716. U.S.A., 117, 33474–33485.
62. Herrera-Nieto,P., Perez,A. and De Fabritiis,G. (2020) Small molecule 74. Tang,J., Fu,J., Wang,Y., Li,B., Li,Y., Yang,Q., Cui,X., Hong,J., Li,X.,
modulation of intrinsically disordered proteins using molecular Chen,Y. et al. (2020) ANPELA: analysis and performance assessment
dynamics simulations. J. Chem. Inf. Model., 60, 5003–5010. of the label-free quantification workflow for metaproteomic studies.
63. Lee,S.H., Ahn,S. and Kim,M.H. (2020) Comparing a query Brief. Bioinform., 21, 621–636.
compound with drug target classes using 3D-chemical similarity. Int. 75. Li,B., Tang,J., Yang,Q., Li,S., Cui,X., Li,Y., Chen,Y., Xue,W., Li,X.
J. Mol. Sci., 21, 4208. and Zhu,F. (2017) NOREVA: normalization and evaluation of
64. Skalic,M., Sabbadin,D., Sattarov,B., Sciabola,S. and De Fabritiis,G. MS-based metabolomics data. Nucleic Acids Res., 45, W162–W170.
(2019) From target to drug: generative modeling for the multimodal 76. Naveja,J.J., Stumpfe,D., Medina-Franco,J.L. and Bajorath,J. (2019)
structure-based ligand design. Mol. Pharm., 16, 4282–4291. Exploration of target synergy in cancer treatment by cell-based